The Children's Hospital of Philadelphia

Decode Genetics Ehf

Icahn School of Medicine at Mount Sinai

University of California

University of Pennsylvania

The Royal Institution for the Advancement of Learning/mcgill University

Hakon Hakonarson

Charlly Kao

Joseph Glessner

Patrick Sleiman

Jonathan Paul Bradfield

Michael M Grunstein

Struan F A Grant

Constantin Polychronakos

Yun Rose Li

Lifeng Tian

Haitao Zhang

Terri Helman Finkel

Brendan Keating

Struan Grant

Lyam Vazquez

John A Martignetti

Dong Li

Michael March

Berta Almoguera

Jordan Orange

Charily Kao

Yoav Dori

Christopher Cardinale

Liza Squires

Christoph Seiler

Alvaro Gutierrez-Uzquiza

Zhi-liang Wu

Kenny Nguyen

Marcin Imielinski

Dexter Hadley

Garry A Neil

Xiao Chang

Struan Frederick Airth Grant

Rahul Pandey

Hui-Qi Qu

Josephine Elia

Patrick M A Sleiman

Tara Wenger

Kai Wang

Brett Abrahams

Dan Geschwind

Maja Bucan

Edward Herman

John A Martinetti

Struan FA Grant

Johnathan P Bradfield

Compositions and methods for the diagnosis and treatment of lymphatic anomaly are disclosed.

Compositions and methods for the diagnosis and treatment of lymphatic system disorders

Compositions and methods for the detection and treatment of ADHD are provided.

Association of genetic variations to diagnose and treat attention-deficit hyperactivity disorder (ADHD)

This application relates to methods of treating attention deficit hyperactivity disorder (ADHD), 22q deletion and/or duplication syndrome, and co-morbidities with a nonselective activator of metabotropic glutamate receptors, such as fasoracetam, for example, in subjects having a genetic alteration in at least one metabotropic glutamate receptor (mGluR) network gene.

Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22Q syndrome

Compositions and methods for diagnosing and treating asthma and asthma patients a Th2 high asthma phenotype are disclosed.

Compositions and methods targeting the Th2 pathway for the treatment of asthma

Methods and uses for diagnosing and treating anxiety disorders are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.

Methods of diagnosing and treating anxiety disorder

Methods for diagnosing and treating conduct disorder are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.

Methods of diagnosing and treating conduct disorder

This application relates to methods of diagnosing and treating anorexia nervosa (AN) and binge eating disorder (BED) with a nonselective activator of metabotropic glutamate receptors (mGluRs).

Nonselective metabotropic glutamate receptor activators for treatment of anorexia nervosa and binge eating disorder

This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes.

Methods for use in the diagnosis of autoimmune diseases

This disclosure relates to the identification of a subset of mGluR network gene CNVs that are predictive of efficacy of treatment with fasoracetam, as well as the identification of an mGluR network gene CNV that is predictive of an increased likelihood of having ADHD as well as having certain symptoms associated with ADHD.

Methods of diagnosing and treating ADHD in biomarker positive subjects

Compositions and methods useful for the diagnosis and treatment of juvenile idiopathic arthritis are disclosed.

CXR4 as a susceptibility locus in juvenile idiopathic arthritis (JIA) and methods of use thereof for the treatment and diagnosis of the same

Compositions and methods for the treatment of amyloid deposit diseases, e.g., hereditary cystatin C amyloid angiopathy and other neurodegenerative disorders, are disclosed.

Compositions and methods for treatment of hereditary cystatin C amyloid angiopathy (HCCAA) and other neurodegenerative disorder associated with aberrant amyloid deposits

Methods and uses for diagnosing and treating Tourette syndrome are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.

Methods of diagnosing and treating Tourette syndrome

Methods for diagnosing and treating autism spectral disorders are encompassed. In one embodiment, a patient is diagnosed as having autism spectral disorder if at least one CNV in an mGluR network gene is found in a patient sample. Patients with at least one mGluR network gene CNV are effectively treated with (+)-5-oxo-Dprolinepiperidinamide monohydrate (NS-105).

Methods of diagnosing and treating autism

Growing community of inventors

Malvern, PA, United States of America

Hakon Hakonarson